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Background: Effective therapeutic strategies are available to prevent adverse outcomes in patients with chronic
kidney disease (CKD) but their clinical results are hindered by unplanned implementation. Coordination of care
emerges as a suitable way to improve patient outcomes. In this study, we evaluated the effect of planned and
coordinated patient management within a dedicated renal care network comparatively to standard renal care
delivered in nephrology departments of teaching hospitals.
Methods: This observational matched cohort study included 40 patients with CKD stage 4–5 in the network group
as compared with a control group of 120 patients matched for age, sex and diabetic status. Main outcome was a
composite endpoint of death from cardiovascular cause and cardiovascular events during the first year after dialysis
initiation.
Results: There was no difference between the two groups neither for the primary outcome (40% vs 41%) nor for
the occurrence of death from cardiovascular cause or cardiovascular events. Whereas the proportion of patients
requiring at least one hospitalization was identical (83.3% vs 75%), network patients experienced less individual
hospitalizations than control patients (2.3±2.0 vs 1.6±1.7) during the year before dialysis start. Patients of the
network group had a slower renal function decline (7.7±2.5 vs 4.9±1.1 ml/min/1,73m2 per year; p=0.04).
Conclusions: In this limited series of patients, we were unable to demonstrate a significant impact of the
coordinated renal care provided in the network on early cardiovascular events in incident dialysis patients.
However, during the predialysis period, there were less hospitalizations and a slower slope of renal function
decrease.
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progressionBackground
Chronic Kidney Disease (CKD) is a growing concern in
developed and developing countries. The continuous in-
crease in the number of prevalent End-Stage Renal Dis-
ease (ESRD) patients led to an increased burden of care
for patients and of expenses for the health care system
[1]. A critical issue is the identification of patients with* Correspondence: laville@univ-lyon1.fr
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reproduction in any medium, provided the orthe highest risk of adverse outcomes, using currently
available markers [2]. Another major issue is the most
efficient way to deliver appropriate care to these
patients.
Although efficient therapeutic interventions to prevent
CKD progression exist since almost two decades, they
seem to have had only limited impact on ESRD inci-
dence during this period [3,4]. This lack of clear benefit
is likely due to suboptimal cares, which can be observed
both when the patient is followed by the general practi-
tioner (GP) and/or the nephrologist [5-7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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onment and some degree of therapeutic inertia related to
physician’s behaviour are suspected to play a key role in
poor therapeutic efficiency [8,9]. This has led to questions
about the way to deliver renal care more efficiently. Multi-
disciplinary renal clinics (MDRC) [10] and renal care
networks [11] both offer an integrative way to provide op-
timal renal cares. In patients with diabetes mellitus,
studies have found positive effects of this type of care de-
livery on patient’s outcomes [12,13]. In CKD patients, sev-
eral studies have also found some positive effects of
MDRC comparatively to standard care on renal outcomes
[14-18]. Presently, the best way to organize those multidis-
ciplinary renal clinics is, however, not standardized. To
our knowledge, there is only one experience reported
concerning the effects of renal care networks [11]. We
therefore undertook a prospective matched cohort study
in order to assess the effects of prior management by a
renal care network on early mortality and outcomes in in-
cident patients on dialysis.
Methods
The study was conducted in accordance with the
principles of the declaration of Helsinki. The local
ethical committee (Comité de protection des personnes
SUD-EST IV, Lyon, France) approved the study protocol.
The committee did not recommend obtaining informed
consent from patients enrolled in this study because the
data were analysed anonymously. This was a multicenter,
prospective, matched-cohort study. The exposed patients
were followed in the TIRCEL network (Traitement de
l’Insuffisance Rénale Chronique en rhônE-aLpes), which
is a coordinated care network dedicated to CKD patients
in the Rhône-Alpes area. The management of patients in
the network has been fully described elsewhere [19].
Briefly, there were standardized protocols for monitoring
the patient’s clinical and biological status. The frequency
of monitoring was based on the level of severity of CKD.
To avoid losing sight of patients, they were contacted by
telephone by members of the coordination of the net-
work when they were not attended to a scheduled con-
sultation. Educational sessions were proposed to the
patients on a voluntary basis. The educational sessions
and materials were built according to the French
guidelines on patient’s education. Some cardiovascular risk
factors, like Blood Pressure (BP) control and how to reach
optimal blood level of cholesterol were specifically
addressed during the educational sessions. At 12/31/2011,
the network included 985 patients with 22.6% stage 4–5
CKD patients. The patients of the control group were all
followed up in the nephrology department of one of the
following hospitals which are all teaching hospitals located
outside of the area covered by the network: Saint Etienne,
Bordeaux, Limoges, Clermont Ferrand and Paris-Bichat.Those patients underwent standard care, which in-
cluded periodic visits, and biological assays with frequency
based on the level of glomerular filtration rate (GFR). A
dedicated nurse rather than the physician gave informa-
tion and preparation for dialysis.
All patients aged over 18 years, benefiting from social
insurance and who started maintenance dialysis between
January 2004 and August 2009 could be included. We
chose the period just around the start of dialysis because
dialysis patients have the greatest mortality rate during
the first year of dialysis treatment. Moreover, suboptimal
care during the period just before the start of dialysis can
have serious consequences for patients with stage 4–5
CKD and we assumed that there is a potential for improv-
ing the management of patients during this period. Finally
only patients who actually started dialysis treatment were
included. During the study period, all of the 40 network
patients who started dialysis were included in the analysis.
Each network patient was individually matched for age,
sex, diabetic status and dialysis start time with three ran-
domly chosen control patients coming from 3 different
nephrology departments (Figure 1).
Data collection
Patient data were recorded retrospectively from 12
months before dialysis then prospectively for 12 months
after the beginning of dialysis. The data were collected
from either electronic or written medical records. All the
data from medical visits and biological measurements,
including at dialysis start, were collected over the pre-
dialysis year. Over the first dialysis year, all events occur-
ring within and between dialysis sessions were recorded.
Estimated GFR (eGFR) was calculated by using simplified
MDRD equation [20]. Measurement of BP was made in
sitting position at rest during physician visit.
Endpoints
The primary endpoint was the occurrence of cardiovascu-
lar events or death from cardiovascular cause during the
first year on dialysis. Cardiovascular events were defined
as one of the following events: myocardial infarction, con-
gestive heart failure, ischemic or haemorrhagic stroke,
acute lower limb ischemia, lower limb amputation.
The secondary endpoints were death from any cause
and hospitalizations during the first year on dialysis. Dur-
ing the year before entering dialysis, we also studied the
following events:
-Number of hospitalizations and slope of eGFR decline;
-Frequency of medical and dietetic visits and of
monitoring of biological relevant parameters
-Prescription of blockers of renin-angiotensin system
(RAS), beta-blockers, antiplatelet agents, and lipid-
lowering drugs; rate of patients reaching target values
12 Centers 
40 patient followed within  
the renal care network 
120 patient followed within  
the nephrology department  
of a teaching hospitals 
Thirteen patients deceased  
or transplanted 
Twenty six patients deceased 
or transplanted 
M12 before  
dialysis 
Dialysis start 
M12 after  
dialysis 
Figure 1 Flow-chart of the study.
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parameters
-Individual and dedicated information on dialysis
treatments received by patients, rate of emergency first
dialysis, rate of initial use of sustainable dialysis access,
registration on transplantation waiting list.Statistical analysis
Characteristics of our study samples were compared to
national data by one-sample Student t-tests (for means)
or one-sample z-tests (for proportions). Variables were
presented as mean, standard deviation for quantitative
variables and as percentage for qualitative variables. Sur-
vival was estimated by the product-limit procedure of
Kaplan Meier, and survival curves were compared with
the log rank test. Biological or clinical parameters were
compared using conditional logistic regression [21]. The
calculation of the samples size, with α=0.05 and 1-β=0.8
were based on the following assumptions: risk of one
year mortality or cardiovascular events of 20% with the
follow up in the network allowing to decrease this risk
to 5%. We found that 38 patients had to be included in
the network group and 114 in the control group. As-
suming a proportion of patient lost of follow up of al-
most 5%, we included 40 patients in the network group
and 120 in the control group.
The GFR annual slope was computed with all values
available between 12 months before dialysis and dialysis
starting date. This slope was compared between the
network group and the control group with a mixed mo-
del accounting for matching [22,23]. Using regression
equations, we defined the theoretical value for entering
dialysis. Only parameters with less than 15% of missing
data were considered. Statistical analysis was performedusing SAS 9.2 software (SAS Institute Inc., North
Carolina, USA) and the threshold of 0.05 was considered
as statistically significant.Results
Patient characteristics
As expected from the matching, the patients from the
two groups had similar age, gender and prevalence of
diabetes (Table 1). The distribution of primary renal dis-
ease was similar except for the percentage of patients
with hereditary nephropathies that was significantly
higher in the network group.
In order to verify the representativeness of the two
groups of patients, we compared major characteristics of
study patients to those of incident dialysis patients
registered during the same period in the French national
database of ESRD patients, the REIN (Renal Epidemi-
ology Information Network) Registry. In the whole study
group, there were no differences for age and the propor-
tion of women (respectively 65.6±14.7 vs 65.3±15.6 and
35% vs 38%) but there were less diabetic patients (22.5%
vs 33.8%; p<0.003) and fewer patients with unknown/
others primary renal disease (3.1% vs 12.2%; p<0.0001)
than in national database patients.Primary endpoints
During the first 12 months of dialysis, 16 events (40%) oc-
curred in the network patients whereas 49 events (40.8%)
occurred in the control patients (p=0.92, Figure 2). A car-
diovascular event occurred in 15 network patients (37.5%)
and 46 control patients (38.3%) (p=0.92). The death from
cardiovascular cause occurred in 3 network patients
(7.5%) and in 8 control patients (6.7%) (p=0.85).
Table 1 Clinical characteristics of patients at inclusion (i.e. 12 months before dialysis initiation)
Characteristics Whole population Control (n=120) Network (n=40) p
Age (years) 65.6 ± 14.7 65.6 ± 14.6 65.5 ± 15.4 0.62
Sex (% females) 35.0 35.0 35.0 -
Diabetes (%) 22.5 22.5 22.5 -
Non-smoker (ever) (%) 54.4 55.1 56.4 0.95
BMI (kg/m2) 26.0 ± 5.3 26.2 ± 5.5 25.3 ± 4.4 0.33
eGFR at inclusion (ml/min/1.73m2) 14.9 ± 7.3 15.2 ± 8.2 14.2 ± 4.5 0.54
Primary renal disease (%)
-
Glomerulonephritis
26.3 26.7 25.0 0.83
-
Diabetic nephropathy
16.9 18.3 12.5 0.1
-
Vascular nephropathies
28.1 30.8 20.0 0.15
-
Tubulo-interstitial nephropathies
9.4 8.3 12.5 0.45
-
Hereditary nephropathies
16.3 12.5 27.5 0.02
-
Others
1.9 1.7 2.5 0.74
-
Unknown




95.0 94.2 97.5 0.43
-
Heart Failure
17.5 17.5 17.5 -
-
Previous MI
10.0 9.2 12.5 0.55
-
Previous Stroke or TIA
11.9 14.2 5.0 0.12
-
Lower limb vascular disease
25 27.5 17.5 0.16
-
Respiratory Failure
16.9 15.8 20.0 0.53
-
Cancer
20.0 22.5 12.5 0.16
(MI= Myocardial Infarction, TIA=Transient Ischemic Attack).
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Five network patients (12.5%) and 17 control patients
(14.2%) died during the first year after dialysis start and 22
network patients (55%) and 80 control patients (66.7%)
required at least one hospitalization (respectively p=0.79
and p=0.19). The mean number of hospitalizations per pa-
tient was significantly higher in the control group (2.0±2.3
vs 1.2±1.6; p=0.03).
During the year before dialysis, 30 network patients
(75%) and 100 control patients (83.3%) required at least
one hospitalization (p=0.24). The mean number of
hospitalizations per patient was significantly higher in the
control group (2.3±2.0 vs 1.6±1.7; p=0.04). Hospitali-zations needed to start dialysis were more frequent in the
control group (32.5% vs 12.5%; p=0.02).
The slope of eGFR decline was significantly slower in
the network group (7.7±2.5 vs 4.9±1.1 ml/min/1.73m2
per year; p=0.04) (Figure 3). The eGFR value at inclusion
was similar between the two groups (Table 1) but was
significantly higher at dialysis start in network patients
(Table 2) which could have spent 4.4 months longer
without dialysis before reaching the same eGFR value
than control patients (i.e. 9.0 ml/min/1.73m2).
During the 12 months before the start of the dialysis,
network patients had more nephrology visits (5.6±2.5 vs
4.5±2.5; p=0.02). The proportion of patients without a
Figure 2 Event-free survival (cardiovascular events or cardiovascular death) using Kaplan-Meier estimates on 160 patients
(log-rank p-value=0.9706).
Figure 3 Comparison of the slope of eGFR decline
between groups.
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tively to the network group (89.2% vs 40%; p<0.001).
The mean total number of encounters with health pro-
fessionals was higher for the network patients (8.8±3.6 vs
6.5±3.7; p=0.003) as was the frequency of measurement of
relevant biological parameters (Table 3).
Concerning medications taken by the patients, 151
patients received at least one BP lowering agent (95% vs
92.5% for control and network groups, respectively;
p=0.55). Amongst them, 115 received at least one blocker
of the RAS (73.7% vs 83.8% for control and network
groups, respectively; p=0.18). Sixty-two patients received a
beta-blocker (41.7% vs 30% for control and network
groups respectively; p=0.2). Fifty-five patients received an
antiplatelet agent (33.3% vs 37.5% for control and network
groups respectively; p=0.6). One hundred and thirty-five
patients received a lipid-lowering drug (82.5% vs 90% for
control and network groups respectively; p=0.26). Among
the 115 patients receiving at least one medication to cor-
rect anaemia, 105 patients received an erythropoiesis
stimulating agent (89.7% vs 96.4% for control and network
Table 2 Comparisons of the level of several parameters at the time of the beginning of dialysis
Parameter Control Network p
Systolic BP < 130 mmHg (%) 24.5 28.6 0.67
Diastolic BP < 80 mmHg (%) 57.1 62.9 0.53
BP < 130/80 mmHg (%) 20.0 25.7 0.49
BP < 140/90 mmHg (%) 42.9 34.3 0.29
Serum Creatinine (μmol/L) 643 ± 242 535 ± 202 0.009
eGFR (ml/min/1.73m2) 8.6 ± 3.6 10.3 ± 3.4 0.012
Serum Potassium (mmol/L) 4.5 ± 0.8 4.4 ± 0.5 0.82
Serum Urea (mmol/L) 36.0 ± 12.0 31.0 ± 12.0 0.08
Serum Bicarbonates (mmol/L) 21.4 ± 5.0 21.3 ± 5.0 0.97
Serum Calcium (mmol/L) 2.15 ± 0.28 2.24 ± 0.24 0.06
Serum Calcium [2.1-2.6 mmol/l] (%) 60.0 71.8 0.21
Serum Phosphate (mmol/L) 1.95 ± 0.63 1.67 ± 0.58 0.01
Serum Phosphate [0.9-1.5 mmol/l] (%) 20.7 46.2 0.003
Serum Albumin (g/L) 34.9 ± 6.7 37.1 ± 4.8 0.13
Serum Albumin > 35g/L (%) 55.6 75.9 0.03
Haemoglobin (g/L) 105.2 ± 18.1 110.7 ± 15.3 0.1
Haemoglobin [> 110g/L] (%) 37.9 53.9 0.11
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either by oral or iv route (44.8% vs 46.4% for control and
network groups respectively; p=0.99). Ninety-one patients
from the control group (75.8%) and 36 patients from the
network group (90%) received a treatment for the
prevention of CKD-mineral bone disease (p=0.06). There
was no difference between groups for the prescription ofTable 3 Comparisons of the frequency of several biological te















24h-Urine Urea 0specific components of the treatment (namely calcium
salts, vitamin D, or calcimimetics).
Before the first dialysis session, the achievement
of treatment goals regarding BP was identical in the
two groups (Table 2). The control of serum phos-
phate and albumin levels was better in the network
group (Table 2).sts in the year before dialysis initiation
ontrol Network p
.8 ± 2.6 8 ± 2.7 0.01
.8 ± 2.9 7.3 ± 2.7 0.006
.2 ± 2.7 7.8 ± 2.7 0.002
.1 ± 2.9 6.5 ± 3 0.01
.6 ± 2.9 6.7 ± 2.8 0.03
.3 ± 2.8 6.6 ± 2.9 0.01
.1 ± 1.2 2.3 ± 2 < 0.001
.4 ± 0.7 0.6 ± 0.8 0.14
.7 ± 2.2 1.4 ± 1.6 0.52
.3 ± 1.5 2.1 ± 1.4 0.01
.2 ± 2.9 7.3 ± 2.8 0.04
.8 ± 1.8 2.8 ± 2.3 0.006
.4 ± 1.6 1.6 ± 1.7 0.48
.1 ± 1.5 1.7 ± 1.9 0.05
.9 ± 1.5 1.6 ± 1.8 0.04
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dialysis management issues (Table 4).
Discussion
Despite the lack of difference on the primary endpoint,
the main finding of our study is that patients treated in a
dedicated renal care network were less frequently
hospitalized both during the year before and after dialysis
start. Moreover, they enter dialysis with better control of
serum phosphate, higher proportion of normal serum al-
bumin and received more frequently educations and
information’s sessions on CKD and dialysis techniques. Fi-
nally, they progressed more slowly towards ESRD. This
could have a major impact on the quality of life of the
patients, and on the economical burden of renal care [24].
Regarding the impact of MDRC on the early survival
of incident dialysis patients, our results differ from pre-
vious studies. In a case–control study, Curtis and
colleagues showed that exposure to MDRC of CKD
patients was associated with a better survival [15]. How-
ever, in Curtis et al. Study the mortality rate was rather
high likely because of a greater proportion of diabetic
patients. Despite the lack of information regarding other
comorbidities, it cannot be excluded that patients fromTable 4 Comparisons of several patient conditions between t
Patient condition
Received information on dialysis (%)
Information delivered at a nephrology visit (%)
Attended education sessions (%)






Use of sustainable dialysis access for first dialysis (AV fistula or catheter) (%)







Type of dialysis facility at 12 months:
-





Pre-dialysis registration on transplant waiting list (%)
Registration on transplant waiting list within the first year on dialysis (%)the study by Curtis et al. were at higher risk than ours,
resulting in an enhanced effect of therapeutic interven-
tion [15]. Similarly, in a cohort study, Goldstein and
colleagues found a better survival and fewer hospita-
lizations in patients followed in MDRC before dialysis, as
compared to patients receiving standard care [16]. This
difference could be also due to a higher basal risk of death
and cardiovascular events, because of a higher proportion
of patients with diabetes and/or previous cardiovascular
diseases. In line with the hypothesis that the effect of net-
work care was minimized by the recruitment of patients
at relatively low risk, the comparison with the whole
population of contemporary incident dialysis patients
within the REIN Registry showed a lower prevalence of
diabetes (22.5% versus 41%) and heart failure (17.5%
versus 28.1%) amongst the study patients, resulting in a
lower mortality rate during the first year on dialysis
(13.8% versus 17%) [3]. In addition, in our study, the rate
of use of cardiac and renal protective medications was
higher (almost 93% for blockers of RAS) than previously
observed [25], and did not differ between the two groups.
This may have contributed to the lack of differences on
the primary endpoint. The percentage of patients taking

















Rognant et al. BMC Nephrology 2013, 14:41 Page 8 of 10
http://www.biomedcentral.com/1471-2369/14/41close from the figures reported previously [26-28]. Finally,
the length of follow-up in our study could have been too
short to detect differences on major outcomes. It is note-
worthy that Curtis and colleagues found only a slight dif-
ference on survival curves after one year of follow up [15]
between the MDRC and the control groups.
Network patients required fewer individual hospita-
lizations before and after the beginning of dialysis, as well
as for first dialysis session. There was a trend towards a
decrease of unplanned first dialysis and an increase of the
proportion of sustainable access used for this first dialysis
(Table 4). This occurred despite a higher proportion of
patients with usable and sustainable access for first dialysis
in the control group comparatively to the mean propor-
tion in the REIN registry (69.2% vs 63%) [3], that suggests
a high quality of care for the creation of dialysis access.
The eGFR at dialysis initiation in network patients was
similar to that observed in the REIN registry (9.6 ml/
min/1,73m2) [3], but it was lower in the control group.
This difference in average eGFR at dialysis initiation has
had probably no impact on the primary outcome and on
the one-year mortality rate. Indeed, the IDEAL study
showed that there were no difference in the one-year mor-
tality rate between two randomized groups of patients
who started dialysis respectively with 9.0 and 7.2 ml/min/
1,73m2 of average eGFR [29]. Even if the impact of this
difference is not known on the occurrence of cardiovascu-
lar events during, it seems unlikely that there could be an
impact on the primary outcome of our study. So patients
from the control group were theoretically more prone to
develop metabolic and nutritional disorders, as shown by
the lower proportion of patients with normal serum phos-
phate and albumin levels at dialysis initiation (Table 2).
However, some others relevant biological parameters
were not different between groups. The decreased rate of
hospitalizations is likely related to a lower occurrence of
complications, including those requiring unplanned dialy-
sis like electrolytic disorders or acute pulmonary oedema.
The incidence of these complications could be positively
affected by educational sessions about lifestyle changes
and by visits with trained dieticians, which were more fre-
quent in the network patients.
An interesting result of our study is that network
patients had a slower decline of renal function (Figure 3),
with the dialysis start virtually postponed by more than 4
months. Those results are consistent with previous
findings by Devins et al. and more recently by Bayliss et al.
[14,30]. Devins and colleagues showed in a randomized
controlled trial that a psycho-educational intervention
added to usual care allowed delaying dialysis start by 3
months. Educational sessions were also included in our
network care and may contribute to the observation of
close results between the study by Devins et al. and ours
[30]. The results of the observational study by Bayliss andcolleagues showed a slow-down of eGFR decrease. This
study included patients with a large proportion of diabetes
and obesity, a higher baseline eGFR and slower decline
than in our study. The control of diabetes and BP was
similar in the two groups, suggesting an impact of the
MDRC intervention on other progression factors such as
dietary habits or use of nephrotoxic medications [14].
The proportion of patients with hereditary diseases was
higher in the network group (Table 1). Differences in the
distribution of primary nephropathies might have had an
influence on the results. However, in advanced stages of
CKD, the nature of primary renal disease has only a minor
influence on the slope of eGFR decrease [31]. Therefore,
the differential progression of CKD is more likely related
to the difference in renal care organization.
Our study was designed to assess the effects of
coordinated renal care within a distributed network in-
volving healthcare professionals working in the commu-
nity. At the difference of centralized MDRC in which
the services are provided within a same centre [15,16], the
network allows the patients to maintain ambulatory en-
counters with family practitioners. In addition, it provides
a biological monitoring closer to CKD management
guidelines than usual renal care (Table 2). This could
explain the favourable impact of network care on CKD
progression. A recent study by Hotu et al. showed that in
diabetic and hypertensive CKD patients, a community
based model of care leads to a higher decrease in
proteinuria and BP than in patients receiving usual care
[18]. To our knowledge, this issue was addressed by only
one observational study [11]. The authors showed that a
distributed network could improve the progression of
CKD in patients with stage 3–5 CKD comparatively
to usual care. However, in this study, renal follow up was
only performed by the GP, without visits with the nephro-
logist who gave the treatment adaptations remotely [11].
This is quite different from our approach because the ab-
sence of direct contact between patients and nephrologist
may affect the clinical evolution of the patients.
This study describes for the first time in France the
effects of coordinated renal care provided by a dedi-
cated network. Although accurate epidemiological data on
the treatment of stages 4–5 CKD are lacking, data from
the REIN registry show a trend towards a stabilization of
the incidence rate of ESRD over the five last years. How-
ever, the prevalence of CVD remains high in incident
patients, contributing to their early mortality: French data
network REIN showed that the risk of death is highest in
the first year after the start of dialysis treatment (17% for
the whole population), especially in older patients [3]. In a
context of a public social insurance allowing virtually un-
limited access to renal caregivers, a way to improve the
results of the health system could be to implement new
therapeutic strategies based on care coordination through
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system, as in several countries, is actually subject to an
economic pressure because the resources allocated tend
to become limited and care cost is becoming more expen-
sive (due to the aging of the population and to several
others reasons like incoordination of some provided care).
Therefore care network could also help to reduce the
costs related to the management of ESRD, which is pres-
ently crucial because it is a costly disease.
These results must be interpreted in the light of some
limitations of the study. The two main limitations are
related to the design of the study. This was an observa-
tional matched cohort study and although patients were
matched on important confounders, it cannot be
excluded that some others confusion parameters may
have influenced the results. Another limitation was the
difficulty to collect retrospective data from 24h urine
measurements that precluded any analysis of the rela-
tionship between proteinuria and outcomes. However,
the predictive value of proteinuria on cardiovascular
events has been mainly assessed in earlier CKD stage
patients [2] and it is unclear if the inclusion of protein-
uria would have changed the meaning of the results in
our late 4–5 CKD stage patients. Finally, one other limi-
tation to mention is that our study was only interested
by patients with stages 4–5 CKD. It can be speculated
that the results could have been different with patients
who wouldn’t have started dialysis (being treated only
conservatively) or in patients with less severe CKD (i.e.
stage 3 CKD).Conclusions
In conclusion, our study shows that a dedicated renal
cares network based on a distributed design is effective
to decrease the rate of hospitalizations either in the year
before and after dialysis initiation. Moreover, it could
lower the slope of GFR decrease in patients with
advanced CKD. Although no effects of the network were
observed concerning the primary endpoint, this could
result from a short follow-up period or being related to
the CKD stages of the included patients. These results
suggest that the management of patients with CKD in a
renal care network could improve some of the patient’s
outcomes but further studies are needed to confirm this
positive effect.Abreviations
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